neurology

News

AbbVie's Cerevel takeover delivers Parkinson's approval

The first drug from AbbVie's $8.7 billion takeover of Cerevel two years ago, Parkinson's disease therapy Juvmo, has won FDA approval.

News

Iambic files IPO after signing up AbbVie as new partner

In the space of a day, Iambic has filed an IPO, released the latest version of its AI platform, and signed a multi-year alliance with AbbVie.

News

Reviews underway of first drug for rare disease MOGAD

Patients with rare autoimmune disease MOGAD could be months away from having a first approved therapy, as the FDA starts a review of Roche's Enspryng.

News

Person holds hand of elderly lady; grey colour scheme

Major trial of Roche Alzheimer's drug kicks off in Europe

The PrevenTRON trial of Roche's Brainshuttle drug trontinemab in preclinical Alzheimer's disease has gotten underway in the UK.

News

Novartis sets sights on new oral MS drug after phase 3 wins

Novartis' oral BTK inhibitor remibrutinib has shown efficacy in a pair of phase 3 trials in multiple sclerosis, boosting its blockbuster credentials.

News

Centre for Ageing image of seated exercise class

Alzheimer's patients 'not changing brain health behaviours'

Researchers have found that people with early Alzheimer's are not following guidelines for promoting brain health, even if they are on drug therapy.

AbbVie's Cerevel takeover delivers Parkinson's approval

Iambic files IPO after signing up AbbVie as new partner

Reviews underway of first drug for rare disease MOGAD

Major trial of Roche Alzheimer's drug kicks off in Europe

Novartis sets sights on new oral MS drug after phase 3 wins

Alzheimer's patients 'not changing brain health behaviours'

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

neurology

Editor's Picks